U.S. Markets closed

Admedus Ltd, Product Pipeline Analysis - Updated 2019 - ResearchAndMarkets.com

The "Admedus Ltd (AHZ) - Product Pipeline Analysis, 2019 Update" company profile has been added to ResearchAndMarkets.com's offering.

Summary

Admedus Ltd (Admedus) develops, manufactures and distributes medical devices and technologies with focus on tissue engineering and immunotherapies. Using its proprietary ADAPT engineering process, the company is developing a group of regenerative tissue bio-scaffolds for use in soft tissue repairs. Its flagship product, CardioCel is a regenerative tissue for cardiac repairs and reconstructions. The company also distributes infusion systems including ambulatory pumps, syringe and volumetric pumps, administration accessories, Amnicot finger cot, nasal spray (PCA) device and O'Neil urinary catheters. Admedus is developing next generation vaccines for the treatment and prevention of infectious diseases and cancers with an initial focus on Herpes Simplex Virus (HSV-2) and Human papillomavirus (HPV). Admedus is headquartered in Malaga, Western Australia, Australia.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Admedus Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Key Topics Covered:

  • Admedus Ltd Company Overview
  • Admedus Ltd Company Snapshot
  • Admedus Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Admedus Ltd - Pipeline Analysis Overview
  • Business Description
  • Admedus Ltd - Key Facts
  • Admedus Ltd - Major Products and Services
  • Admedus Ltd Pipeline Products by Development Stage
  • Admedus Ltd Ongoing Clinical Trials by Trial Status
  • Admedus Ltd Pipeline Products Overview
  • ADAPT - Dura Mater Repair
  • ADAPT - Dura Mater Repair Product Overview
  • ADAPT - Half Pipe Conduit
  • ADAPT - Jugular Vein
  • ADAPT - Pediatric Leaflets
  • ADAPT - Samurai
  • ADAPT - Whole Vascular Tissue
  • ADAPT Based Device - Orthopedic
  • CardioCel
  • CardioCel Clinical Trial
  • CardioCel - Hernia Repair
  • Cardiocel - Mitral Valve Repair
  • Cardiocel - Tri-Leaflet Aortic Valve Repair
  • Cardiocel 3D
  • Cardiocel 3D Clinical Trial
  • CardioCel 3D Stage 1 Arch
  • CardioCel Neo
  • CardioCel Neo Clinical Trial
  • GyneCel
  • Transcatheter Aortic Valve Replacement Device
  • VascuCel
  • Admedus Ltd - Key Competitors
  • Admedus Ltd - Key Employees
  • Admedus Ltd - Key Employee Biographies
  • Admedus Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Admedus Ltd, Recent Developments
  • Sep 04, 2019: Admedus Cardiocel 3D approved for sale in Israel
  • Jul 31, 2019: Admedus: Quarterly Report - Appendix 4C for the period to JUNE 2019
  • Jun 24, 2019: Positive data on CardioCel published in leading journal
  • May 08, 2019: Facility agreement signed with Sio Partners
  • May 08, 2019: Facility agreement signed with Sio Partners
  • Apr 26, 2019: Admedus: Quarterly Report - Appendix 4C for the period to 31 March 2019
  • Mar 11, 2019: Admedus receives European CE Mark for CardioCel 3D and VascuCel
  • Feb 28, 2019: Admedus: Preliminary final report - Appendix 4E for the period to 31 December 2018
  • Feb 19, 2019: Admedus: Promising interim results from TAVR animal study
  • Jan 30, 2019: Admedus: Change of registered address
  • Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer

Companies Mentioned

  • Medtronic Australasia Pty Ltd
  • Nexstim Plc
  • Biotron Ltd
  • Benitec Biopharma Ltd

For more information about this company profile visit https://www.researchandmarkets.com/r/dmf6su

View source version on businesswire.com: https://www.businesswire.com/news/home/20200214005253/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900